Autolus Therapeutics (NASDAQ:AUTL) Shares Down 5.8% – What’s Next?

Shares of Autolus Therapeutics plc (NASDAQ:AUTL) were down 5.8% on Tuesday . The stock traded as low as $3.06 and last traded at $3.07. Approximately 126,730 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 1,458,050 shares. The stock had previously closed at $3.26.

Analyst Ratings Changes

Several equities research analysts recently weighed in on AUTL shares. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, November 11th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a report on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $10.15.

Autolus Therapeutics Stock Down 4.7 %

The company has a fifty day moving average of $3.70 and a two-hundred day moving average of $3.89. The stock has a market capitalization of $811.59 million, a price-to-earnings ratio of -2.52 and a beta of 1.98.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the previous year, the firm posted ($0.26) earnings per share. Equities analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AUTL. ProShare Advisors LLC purchased a new position in shares of Autolus Therapeutics in the second quarter valued at $43,000. Capstone Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the third quarter valued at $51,000. Daiwa Securities Group Inc. increased its position in shares of Autolus Therapeutics by 2,659.7% in the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock valued at $55,000 after buying an additional 15,293 shares in the last quarter. Herbst Group LLC purchased a new position in shares of Autolus Therapeutics in the third quarter valued at $91,000. Finally, B. Riley Wealth Advisors Inc. purchased a new position in shares of Autolus Therapeutics in the first quarter valued at $108,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.